Oxford, United Kingdom - October 3, 2025. Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, ...
BOSTON, October 02, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming ...
AURORA, Colo., Oct. 1, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human ...
Shape Therapeutics is leveraging AI to develop new payload, delivery and manufacturing technologies for the gene therapy industry. Alongside the company’s own RNA-targeting gene therapy portfolio, ...
Augurex to present new data from clinical studies in an oral presentation and two poster presentations at ACR Convergence 2025, taking place October 24 29 in Chicago, IL. Professor Raj Sengupta will ...
Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR ...
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster ...
MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced two upcoming oral presentations highlighting the company’s ...
Second oral presentation will provide updated data from GDFATHER-01 trial demonstrating deep and durable remissions in heavily pretreated patients CatalYm, a world-leader in neutralizing GDF-15 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback